...Operator Good day, and welcome to the NIU Phase II top line results call. At this time, all participants are in listen-only mode. After the speaker's remarks, there will be a question-and-answer session. (Operator Instructions) As a reminder, this call is being recorded. I would now like to turn the call over to Jeffrey Kalmus. Please go ahead. Jeffrey Kalmus Good morning, and thank you for joining today's call to review the results from our Phase II study evaluating brepocitnib in non interior non-infection Uveitis. We will also discuss updates on our capital allocation and new share repurchase program. I'm Jeffrey Kalmus with Roivant Sciences. Presenting today, we have Matt Gline, CEO of Roivant; and Benjamin Zimmer, CEO of Priovant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at investor.roivant.com. We'll also be providing the current slide numbers as we present to help...